Retinitis pigmentosa (RP) is a group of genetic eye conditions that leads to incurable blindness.In the progression of symptoms for RP, night blindness generally precedes tunnel vision by years or ...

The median age at onset of symptoms was 20.5 years (range: 8–39) for STGD and 30 years (range: 2–72) for RP, with the median duration of the disease of 11.5 years (range: 0–39) and 14 years ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...

Vision loss is also one of the major, progressive symptoms of X-linked retinitis pigmentosa (XLRP). It is caused by mutations in genes located on the X chromosome, which means the condition ...

Night blindness is caused by vitamin A deficiency, congenital mutations, and other eye diseases. Learn about symptoms, causes ...

In this Healio Video Perspective from the ARVO meeting, SriniVas R. Sadda, MD, FARVO, discusses a long-term study evaluating MCO-010 for the treatment of retinitis pigmentosa.

A breakthrough treatment has allowed damaged retinal cells to regenerate themselves. The current research has been conducted on mice, but the pathways are the same in humans, which opens hope for a ...

STGD Stargardt's Disease, PR pigmentosa retinitis, TE total energy, SFA saturated fats, MUFA monounsaturated fats, PUFA polyunstaurated fats, ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic therapy based on light-sensitive molecules is an effective treatment for incurable eye ...

After being diagnosed with retinitis pigmentosa at four, a condition that causes low vision, she lost most of her sight at 14. “I struggled a lot.